These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 24580044)

  • 21. Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial.
    Sofer E; Boaz M; Matas Z; Mashavi M; Shargorodsky M
    Metabolism; 2011 Sep; 60(9):1278-84. PubMed ID: 21411114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose.
    Han Y; Shi JP; Ma AL; Xu Y; Ding XD; Fan JG
    Clin Drug Investig; 2014 Jan; 34(1):1-7. PubMed ID: 24081374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease.
    Handzlik G; Holecki M; Kozaczka J; Kukla M; Wyskida K; Kędzierski L; Pawlicki K; Duława J
    Pharmacol Rep; 2019 Apr; 71(2):183-188. PubMed ID: 30780126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Of mice and men: Is there a future for metformin in the treatment of hepatic steatosis?
    Green CJ; Marjot T; Tomlinson JW; Hodson L
    Diabetes Obes Metab; 2019 Apr; 21(4):749-760. PubMed ID: 30456918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease.
    Liu J; Wang G; Jia Y; Xu Y
    Diabetes Metab Res Rev; 2015 May; 31(4):329-35. PubMed ID: 25066109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels.
    Pinyopornpanish K; Leerapun A; Pinyopornpanish K; Chattipakorn N
    Gut Liver; 2021 Nov; 15(6):827-840. PubMed ID: 33820884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Non-alcoholic liver disease - diagnosis and treatment].
    Sarosiekjeznach-Steinhagen A; Ostrowska J; Czerwonogrodzka-Senczyna A; Boniecka I
    Pol Merkur Lekarski; 2017 Nov; 43(257):237-242. PubMed ID: 29231919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review. The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease.
    Sun X; Zhang Y; Xie M
    Acta Pharm; 2017 Mar; 67(1):1-13. PubMed ID: 28231052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.
    Musso G; Cassader M; Rosina F; Gambino R
    Diabetologia; 2012 Apr; 55(4):885-904. PubMed ID: 22278337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relevant Aspects of Nutritional and Dietary Interventions in Non-Alcoholic Fatty Liver Disease.
    Hernandez-Rodas MC; Valenzuela R; Videla LA
    Int J Mol Sci; 2015 Oct; 16(10):25168-98. PubMed ID: 26512643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. N-ACETYLCYSTEINE AND/OR URSODEOXYCHOLIC ACID ASSOCIATED WITH METFORMIN IN NON-ALCOHOLIC STEATOHEPATITIS: AN OPEN-LABEL MULTICENTER RANDOMIZED CONTROLLED TRIAL.
    Oliveira CP; Cotrim HP; Stefano JT; Siqueira ACG; Salgado ALA; Parise ER
    Arq Gastroenterol; 2019 Aug; 56(2):184-190. PubMed ID: 31460584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of oral antidiabetic agents and incretin mimetics in type 2 diabetic patients with non-alcoholic fatty liver disease.
    Gouni-Berthold I; Papanas N; Maltezos E
    Curr Pharm Des; 2014; 20(22):3705-15. PubMed ID: 24040873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in metformin for the treatment of non-alcoholic fatty liver disease in children.
    Wu QL; Zeng SX; Peng JY; Yuan Y; Zhu Z; Xie ZC; Huang ZH; Huang JS; Lai JM; Chen JA; Lin MH
    Expert Rev Gastroenterol Hepatol; 2022 Sep; 16(9):863-877. PubMed ID: 36039840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is There a Role for Curcumin Supplementation in the Treatment of Non-Alcoholic Fatty Liver Disease? The Data Suggest Yes.
    Zabihi NA; Pirro M; Johnston TP; Sahebkar A
    Curr Pharm Des; 2017; 23(7):969-982. PubMed ID: 27748192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.
    Miquilena-Colina ME; Lima-Cabello E; Sánchez-Campos S; García-Mediavilla MV; Fernández-Bermejo M; Lozano-Rodríguez T; Vargas-Castrillón J; Buqué X; Ochoa B; Aspichueta P; González-Gallego J; García-Monzón C
    Gut; 2011 Oct; 60(10):1394-402. PubMed ID: 21270117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyperreactivity of Blood Leukocytes in Patients with NAFLD to Ex Vivo Lipopolysaccharide Treatment Is Modulated by Metformin and Phosphatidylcholine but Not by Alpha Ketoglutarate.
    Zwolak A; Szuster-Ciesielska A; Daniluk J; Słabczyńska O; Kandefer-Szerszeń M
    PLoS One; 2015; 10(12):e0143851. PubMed ID: 26629827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of diet and nutritional management in non-alcoholic fatty liver disease.
    Fan JG; Cao HX
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():81-7. PubMed ID: 24251710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation.
    Kim H; Lee K; Lee KW; Yi NJ; Lee HW; Hong G; Choi Y; You T; Suh SW; Jang JJ; Suh KS
    Clin Transplant; 2014 May; 28(5):521-9. PubMed ID: 24579874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review article: Drug therapy for non-alcoholic fatty liver disease.
    Comar KM; Sterling RK
    Aliment Pharmacol Ther; 2006 Jan; 23(2):207-15. PubMed ID: 16393299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.
    Nobili V; Manco M; Ciampalini P; Alisi A; Devito R; Bugianesi E; Marcellini M; Marchesini G
    Clin Ther; 2008 Jun; 30(6):1168-76. PubMed ID: 18640473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.